Last 12 months
Inside the activity.
1 purchase rows · 2632 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 142 |
| Dec 2025 | 0 | 143 |
| Jan 2026 | 0 | 78 |
| Feb 2026 | 0 | 26 |
| Mar 2026 | 0 | 364 |
| Apr 2026 | 0 | 346 |
| May 2026 | 1 | 340 |
| Jun 2026 | 0 | 298 |
| Jul 2026 | 0 | 240 |
| Aug 2026 | 0 | 251 |
| Sep 2026 | 0 | 260 |
| Oct 2026 | 0 | 144 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 19, 2018 Filed Jul 20, 2018 20:23 UTC |
MAHON PAUL AEVP & General Counsel
|
Exercise / conversionShare Tracking Award · Derivative | 6,000 | $0.00 Strike: $61.06 | $0.00 |
DisclosureSEC source: 0001127602-18-023669 · form4.xml · derivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Common Stock · 6,000 shares Expires 2023-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| July 19, 2018 Filed Jul 20, 2018 20:23 UTC |
MAHON PAUL AEVP & General Counsel
|
Disposition to issuerCommon Stock | 6,000 | $124.09 | $744,540.00 |
DisclosureSEC source: 0001127602-18-023669 · form4.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,613 F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| July 19, 2018 Filed Jul 20, 2018 20:23 UTC |
MAHON PAUL AEVP & General Counsel
|
Exercise / conversionCommon Stock | 6,000 | $61.06 | $366,360.00 |
DisclosureSEC source: 0001127602-18-023669 · form4.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| July 06, 2018 Filed Jul 9, 2018 20:02 UTC |
PATUSKY CHRISTOPHERDirector
|
Exercise / conversionShare Tracking Award · Derivative | 3,500 | $0.00 Strike: $51.77 | $0.00 |
DisclosureSEC source: 0001127602-18-022973 · form4.xml · derivative · entry 4 PATUSKY CHRISTOPHER · CIK 0001231427 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,500 shares Expires 2020-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| July 06, 2018 Filed Jul 9, 2018 20:02 UTC |
PATUSKY CHRISTOPHERDirector
|
Disposition to issuerCommon Stock | 3,500 | $120.29 | $421,015.00 |
DisclosureSEC source: 0001127602-18-022973 · form4.xml · nonDerivative · entry 2 PATUSKY CHRISTOPHER · CIK 0001231427 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,370 F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| July 06, 2018 Filed Jul 9, 2018 20:02 UTC |
PATUSKY CHRISTOPHERDirector
|
Exercise / conversionCommon Stock | 3,500 | $51.77 | $181,195.00 |
DisclosureSEC source: 0001127602-18-022973 · form4.xml · nonDerivative · entry 1 PATUSKY CHRISTOPHER · CIK 0001231427 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,870 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| July 05, 2018 Filed Jul 6, 2018 20:06 UTC |
CAUSEY CHRISTOPHERDirector
|
Exercise / conversionShare Tracking Award · Derivative | 750 | $0.00 Strike: $54.77 | $0.00 |
DisclosureSEC source: 0001127602-18-022919 · form4.xml · derivative · entry 3 CAUSEY CHRISTOPHER · CIK 0001237334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 750 shares Expires 2021-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| July 05, 2018 Filed Jul 6, 2018 20:06 UTC |
CAUSEY CHRISTOPHERDirector
|
Disposition to issuerCommon Stock | 750 | $116.95 | $87,712.50 |
DisclosureSEC source: 0001127602-18-022919 · form4.xml · nonDerivative · entry 2 CAUSEY CHRISTOPHER · CIK 0001237334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,175 F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| July 05, 2018 Filed Jul 6, 2018 20:06 UTC |
CAUSEY CHRISTOPHERDirector
|
Exercise / conversionCommon Stock | 750 | $54.77 | $41,077.50 |
DisclosureSEC source: 0001127602-18-022919 · form4.xml · nonDerivative · entry 1 CAUSEY CHRISTOPHER · CIK 0001237334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,925 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| July 05, 2018 Filed Jul 6, 2018 20:05 UTC |
MAHON PAUL AEVP & General Counsel
|
Exercise / conversionShare Tracking Award · Derivative | 6,000 | $0.00 Strike: $61.06 | $0.00 |
DisclosureSEC source: 0001127602-18-022918 · form4.xml · derivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,000 Underlying: Common Stock · 6,000 shares Expires 2023-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| July 05, 2018 Filed Jul 6, 2018 20:05 UTC |
MAHON PAUL AEVP & General Counsel
|
Disposition to issuerCommon Stock | 6,000 | $116.95 | $701,700.00 |
DisclosureSEC source: 0001127602-18-022918 · form4.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,613 F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| July 05, 2018 Filed Jul 6, 2018 20:05 UTC |
MAHON PAUL AEVP & General Counsel
|
Exercise / conversionCommon Stock | 6,000 | $61.06 | $366,360.00 |
DisclosureSEC source: 0001127602-18-022918 · form4.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 20:13 UTC |
SULLIVAN LOUIS WDirector
|
Exercise / conversionShare Tracking Award · Derivative | 1,000 | $0.00 Strike: $54.77 | $0.00 |
DisclosureSEC source: 0001127602-18-022828 · form4.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 1,000 shares Expires 2021-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 20:13 UTC |
SULLIVAN LOUIS WDirector
|
Disposition to issuerCommon Stock | 1,000 | $113.81 | $113,810.00 |
DisclosureSEC source: 0001127602-18-022828 · form4.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,370 F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 20:13 UTC |
SULLIVAN LOUIS WDirector
|
Exercise / conversionCommon Stock | 1,000 | $54.77 | $54,770.00 |
DisclosureSEC source: 0001127602-18-022828 · form4.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| June 29, 2018 Filed Jun 29, 2018 21:36 UTC |
DWEK RAYMONDDirector
|
SaleCommon Stock | 3,240 | $113.07 | $366,352.63 |
DisclosureSEC source: 0001127602-18-022040 · form4.xml · nonDerivative · entry 1 DWEK RAYMOND · CIK 0001231617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $112.80 to $113.77. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 28, 2018 Filed Jun 28, 2018 23:25 UTC |
KURZWEIL RAYDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 1,620 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-021989 · form4.xml · derivative · entry 4 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,620 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F8 · derivative.exercise_date: Restricted stock units were granted on June 28, 2017, and vested on June 28, 2018. The entire number of restricted stock units converted into shares of common stock upon vesting. F8 · derivative.expiration_date: Restricted stock units were granted on June 28, 2017, and vested on June 28, 2018. The entire number of restricted stock units converted into shares of common stock upon vesting. Read SEC document |
| June 28, 2018 Filed Jun 28, 2018 23:25 UTC |
KURZWEIL RAYDirector
|
Exercise / conversionCommon Stock | 1,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-021989 · form4.xml · nonDerivative · entry 1 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares received upon vesting of restricted stock units on June 28, 2018. Restricted stock units converted on a one-for-one basis into shares of common stock. Read SEC document |
| June 28, 2018 Filed Jun 28, 2018 23:21 UTC |
Giltner RichardDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 3,240 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-021988 · form4.xml · derivative · entry 3 Giltner Richard · CIK 0001460472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,240 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F3 · shares: Annual non-employee director grant of restricted stock units, which are awarded and priced each year on the date of the issuer's Annual Meeting of Shareholders. F5 · derivative.exercise_date: Restricted stock units were granted on June 28, 2017, and vested on June 28, 2018. The entire number of restricted stock units converted into shares of common stock upon vesting. F5 · derivative.expiration_date: Restricted stock units were granted on June 28, 2017, and vested on June 28, 2018. The entire number of restricted stock units converted into shares of common stock upon vesting. Read SEC document |
| June 28, 2018 Filed Jun 28, 2018 23:21 UTC |
Giltner RichardDirector
|
Exercise / conversionCommon Stock | 3,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-021988 · form4.xml · nonDerivative · entry 1 Giltner Richard · CIK 0001460472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,240 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares received upon vesting of restricted stock units on June 28, 2018. Restricted stock units converted on a one-for-one basis into shares of common stock. Read SEC document |
| June 28, 2018 Filed Jun 28, 2018 23:31 UTC |
Thompson Tommy GDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 1,620 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-021994 · form4.xml · derivative · entry 4 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,620 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F3 · shares: Annual non-employee director grant of restricted stock units, which are awarded and priced each year on the date of the issuer's Annual Meeting of Shareholders. F7 · derivative.exercise_date: Restricted stock units were granted on June 28, 2017, and vested on June 28, 2018. The entire number of restricted stock units converted into shares of common stock upon vesting. F7 · derivative.expiration_date: Restricted stock units were granted on June 28, 2017, and vested on June 28, 2018. The entire number of restricted stock units converted into shares of common stock upon vesting. Read SEC document |
| June 28, 2018 Filed Jun 28, 2018 23:31 UTC |
Thompson Tommy GDirector
|
Exercise / conversionCommon Stock | 1,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-021994 · form4.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares received upon vesting of restricted stock units on June 28, 2018. Restricted stock units converted on a one-for-one basis into shares of common stock. Read SEC document |
| June 28, 2018 Filed Jun 28, 2018 23:16 UTC |
DWEK RAYMONDDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 3,240 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-021987 · form4.xml · derivative · entry 3 DWEK RAYMOND · CIK 0001231617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,240 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F4 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares. F4 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares. Read SEC document |
| June 28, 2018 Filed Jun 28, 2018 23:16 UTC |
DWEK RAYMONDDirector
|
Exercise / conversionCommon Stock | 3,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-021987 · form4.xml · nonDerivative · entry 1 DWEK RAYMOND · CIK 0001231617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,240 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares received upon vesting of restricted stock units on June 28, 2018. Restricted stock units converted on a one-for-one basis into shares of common stock. Read SEC document |
| June 28, 2018 Filed Jun 28, 2018 23:11 UTC |
PATUSKY CHRISTOPHERDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 1,620 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-021986 · form4.xml · derivative · entry 4 PATUSKY CHRISTOPHER · CIK 0001231427 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,620 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F5 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares. F5 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares. Read SEC document |
| June 28, 2018 Filed Jun 28, 2018 23:11 UTC |
PATUSKY CHRISTOPHERDirector
|
Exercise / conversionCommon Stock | 1,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-021986 · form4.xml · nonDerivative · entry 1 PATUSKY CHRISTOPHER · CIK 0001231427 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares received upon vesting of restricted stock units on June 28, 2018. Restricted stock units converted on a one-for-one basis into shares of common stock. Read SEC document |
| June 28, 2018 Filed Jun 28, 2018 23:05 UTC |
SULLIVAN LOUIS WDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 1,620 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-021985 · form4.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,620 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F6 · derivative.exercise_date: Restricted stock units were granted on June 28, 2017, and vested on June 28, 2018. The entire number of restricted stock units converted into shares of common stock upon vesting. F6 · derivative.expiration_date: Restricted stock units were granted on June 28, 2017, and vested on June 28, 2018. The entire number of restricted stock units converted into shares of common stock upon vesting. Read SEC document |
| June 28, 2018 Filed Jun 28, 2018 23:05 UTC |
SULLIVAN LOUIS WDirector
|
Exercise / conversionCommon Stock | 1,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-021985 · form4.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares received upon vesting of restricted stock units on June 28, 2018. Restricted stock units converted on a one-for-one basis into shares of common stock. Read SEC document |
| June 28, 2018 Filed Jun 28, 2018 22:59 UTC |
CAUSEY CHRISTOPHERDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 1,620 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-021984 · form4.xml · derivative · entry 3 CAUSEY CHRISTOPHER · CIK 0001237334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,620 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F5 · derivative.exercise_date: Restricted stock units were granted on June 28, 2017, and vested on June 28, 2018. The entire number of restricted stock units converted into shares of common stock upon vesting. F5 · derivative.expiration_date: Restricted stock units were granted on June 28, 2017, and vested on June 28, 2018. The entire number of restricted stock units converted into shares of common stock upon vesting. Read SEC document |
| June 28, 2018 Filed Jun 28, 2018 22:59 UTC |
CAUSEY CHRISTOPHERDirector
|
Exercise / conversionCommon Stock | 1,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-021984 · form4.xml · nonDerivative · entry 1 CAUSEY CHRISTOPHER · CIK 0001237334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares received upon vesting of restricted stock units on June 28, 2018. Restricted stock units converted on a one-for-one basis into shares of common stock. Read SEC document |
| June 28, 2018 Filed Jun 28, 2018 22:52 UTC |
Olian Judy D.Director
|
Exercise / conversionRestricted Stock Units · Derivative | 3,240 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-021983 · form4.xml · derivative · entry 4 Olian Judy D. · CIK 0001605729 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,240 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Restricted stock units convert on a one-for-one basis into shares of common stock. F8 · derivative.exercise_date: Restricted stock units were granted on June 28, 2017, and vested on June 28, 2018. The entire number of restricted stock units converted into shares of common stock upon vesting. F8 · derivative.expiration_date: Restricted stock units were granted on June 28, 2017, and vested on June 28, 2018. The entire number of restricted stock units converted into shares of common stock upon vesting. Read SEC document |
| June 28, 2018 Filed Jun 28, 2018 22:52 UTC |
Olian Judy D.Director
|
Exercise / conversionCommon Stock | 3,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-021983 · form4.xml · nonDerivative · entry 1 Olian Judy D. · CIK 0001605729 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares received upon vesting of restricted stock units on June 28, 2018. Restricted stock units converted on a one-for-one basis into shares of common stock. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 23:25 UTC |
KURZWEIL RAYDirector
|
GrantStock Options · Derivative | 4,620 | $0.00 Strike: $112.14 | $0.00 |
DisclosureSEC source: 0001127602-18-021989 · form4.xml · derivative · entry 3 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,620 Underlying: Common Stock · 4,620 shares Expires 2028-06-26 F6 · shares: Annual non-employee director grant of stock options, which are awarded and priced each year on the date of the issuer's Annual Meeting of Shareholders. F7 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 23:25 UTC |
KURZWEIL RAYDirector
|
GrantRestricted Stock Units · Derivative | 1,870 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-021989 · form4.xml · derivative · entry 2 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,870 Underlying: Common Stock · 1,870 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F3 · shares: Annual non-employee director grant of restricted stock units, which are awarded and priced each year on the date of the issuer's Annual Meeting of Shareholders. F4 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares. F5 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 23:33 UTC |
Klein Katherine JDirector
|
GrantStock Options · Derivative | 9,240 | $0.00 Strike: $112.14 | $0.00 |
DisclosureSEC source: 0001127602-18-021996 · form4.xml · derivative · entry 1 Klein Katherine J · CIK 0001625073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,240 Underlying: Common Stock · 9,240 shares Expires 2028-06-26 F1 · shares: Annual non-employee director grant of stock options, which are awarded and priced each year on the date of the issuer's Annual Meeting of Shareholders. F2 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 23:21 UTC |
Giltner RichardDirector
|
GrantRestricted Stock Units · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-021988 · form4.xml · derivative · entry 2 Giltner Richard · CIK 0001460472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F3 · shares: Annual non-employee director grant of restricted stock units, which are awarded and priced each year on the date of the issuer's Annual Meeting of Shareholders. F4 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares. F4 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 23:31 UTC |
Thompson Tommy GDirector
|
GrantStock Options · Derivative | 4,620 | $0.00 Strike: $112.14 | $0.00 |
DisclosureSEC source: 0001127602-18-021994 · form4.xml · derivative · entry 3 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,620 Underlying: Common Stock · 4,620 shares Expires 2028-06-26 F5 · shares: Annual non-employee director grant of stock options, which are awarded and priced each year on the date of the issuer's Annual Meeting of Shareholders. F6 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 23:31 UTC |
Thompson Tommy GDirector
|
GrantRestricted Stock Units · Derivative | 1,870 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-021994 · form4.xml · derivative · entry 2 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,870 Underlying: Common Stock · 1,870 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F3 · shares: Annual non-employee director grant of restricted stock units, which are awarded and priced each year on the date of the issuer's Annual Meeting of Shareholders. F4 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares. F4 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 23:16 UTC |
DWEK RAYMONDDirector
|
GrantRestricted Stock Units · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-021987 · form4.xml · derivative · entry 2 DWEK RAYMOND · CIK 0001231617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F3 · shares: Annual non-employee director grant of restricted stock units, which are awarded and priced each year on the date of the issuer's Annual Meeting of Shareholders. F4 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares. F4 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 23:11 UTC |
PATUSKY CHRISTOPHERDirector
|
GrantStock Options · Derivative | 9,240 | $0.00 Strike: $112.14 | $0.00 |
DisclosureSEC source: 0001127602-18-021986 · form4.xml · derivative · entry 3 PATUSKY CHRISTOPHER · CIK 0001231427 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,240 Underlying: Common Stock · 9,240 shares Expires 2028-06-26 F2 · shares: Annual non-employee director grant of stock options, which are awarded and priced each year on the date of the issuer's Annual Meeting of Shareholders. F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 23:05 UTC |
SULLIVAN LOUIS WDirector
|
GrantRestricted Stock Units · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-021985 · form4.xml · derivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F3 · shares: Annual non-employee director grant of restricted stock units, which are awarded and priced each year on the date of the issuer's Annual Meeting of Shareholders. F4 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares. F5 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 22:59 UTC |
CAUSEY CHRISTOPHERDirector
|
GrantStock Options · Derivative | 9,240 | $0.00 Strike: $112.14 | $0.00 |
DisclosureSEC source: 0001127602-18-021984 · form4.xml · derivative · entry 2 CAUSEY CHRISTOPHER · CIK 0001237334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,240 Underlying: Common Stock · 9,240 shares Expires 2028-06-26 F2 · shares: Annual non-employee director grant of stock options, which are awarded and priced each year on the date of the issuer's Annual Meeting of Shareholders. F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 22:52 UTC |
Olian Judy D.Director
|
GrantStock Options · Derivative | 4,620 | $0.00 Strike: $112.14 | $0.00 |
DisclosureSEC source: 0001127602-18-021983 · form4.xml · derivative · entry 3 Olian Judy D. · CIK 0001605729 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,620 Underlying: Common Stock · 4,620 shares Expires 2028-06-26 F3 · shares: Annual non-employee director grant of restricted stock units and/or stock options, which are awarded and priced each year on the date of the issuer's Annual Meeting of Shareholders. F6 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 22:52 UTC |
Olian Judy D.Director
|
GrantRestricted Stock Units · Derivative | 1,870 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-021983 · form4.xml · derivative · entry 2 Olian Judy D. · CIK 0001605729 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,870 Underlying: Common Stock · 1,870 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F3 · shares: Annual non-employee director grant of restricted stock units and/or stock options, which are awarded and priced each year on the date of the issuer's Annual Meeting of Shareholders. F4 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares. F5 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 21:03 UTC |
MAHON PAUL AEVP & General Counsel
|
Exercise / conversionShare Tracking Award · Derivative | 6,000 | $0.00 Strike: $61.06 | $0.00 |
DisclosureSEC source: 0001127602-18-021850 · form4.xml · derivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 6,000 shares Expires 2023-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 21:03 UTC |
MAHON PAUL AEVP & General Counsel
|
Disposition to issuerCommon Stock | 6,000 | $116.73 | $700,380.00 |
DisclosureSEC source: 0001127602-18-021850 · form4.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,613 F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 21:03 UTC |
MAHON PAUL AEVP & General Counsel
|
Exercise / conversionCommon Stock | 6,000 | $61.06 | $366,360.00 |
DisclosureSEC source: 0001127602-18-021850 · form4.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 20:07 UTC |
CAUSEY CHRISTOPHERDirector
|
Exercise / conversionShare Tracking Award · Derivative | 2,250 | $0.00 Strike: $54.77 | $0.00 |
DisclosureSEC source: 0001127602-18-021387 · form4.xml · derivative · entry 3 CAUSEY CHRISTOPHER · CIK 0001237334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 2,250 shares Expires 2021-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 20:07 UTC |
CAUSEY CHRISTOPHERDirector
|
Disposition to issuerCommon Stock | 2,250 | $117.33 | $263,992.50 |
DisclosureSEC source: 0001127602-18-021387 · form4.xml · nonDerivative · entry 2 CAUSEY CHRISTOPHER · CIK 0001237334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,555 F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 20:07 UTC |
CAUSEY CHRISTOPHERDirector
|
Exercise / conversionCommon Stock | 2,250 | $54.77 | $123,232.50 |
DisclosureSEC source: 0001127602-18-021387 · form4.xml · nonDerivative · entry 1 CAUSEY CHRISTOPHER · CIK 0001237334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.